Can Tavalisse Drive Rigel's Growth Through the Rest of 2025? [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
The drug remains a key top-line driver for the company. Tavalisse, an oral spleen tyrosine kinase (SYK) inhibitor, is approved by the FDA for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The drug is also approved in Europe, the United Kingdom, Japan and some other countries. In the first half of 2025, Tavalisse generated sales of $68.5 million, up around 44% year over year. Per management, sales of the drug are being driven by continued strong new patient demand and the momentum is expected to continue in the second half of 2025. Looking ahead, sales are expected to grow steadily as Rigel expands its commercial footprint and strengthens its marketing infrastructure, driving continued momentum for Tavalisse. Besides Tavalisse, Rigel is also making good progress with its other marketed products, Rezlidhia (olutasidenib) and Gavreto (pralsetinib), which are approved for treating certain c
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid MalignanciesBusiness Wire
- ValGenesis Wraps Up Global ValConnect Innovation Day Series with Hyderabad Event [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (RDY) Q2 2026 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- Dr. Reddy's Laboratories (NYSE:RDY) had its "buy (b-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Aurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025Business Wire
RDY
Earnings
- 7/24/25 - Beat
RDY
Sec Filings
- 12/3/25 - Form 6-K
- 11/28/25 - Form 6-K
- 11/28/25 - Form 6-K
- RDY's page on the SEC website